Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Identifieur interne : 001B21 ( PubMed/Curation ); précédent : 001B20; suivant : 001B22Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.
Auteurs : G Mani Subramanian [États-Unis] ; Paul A. Moore ; Brian B. Gowen ; Aaron L. Olsen ; Dale L. Barnard ; Jason Paragas ; Robert J. Hogan ; Robert W. SidwellSource :
- Chemotherapy [ 1421-9794 ] ; 2008.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Bioterrorisme, Ebolavirus (), Ebolavirus (physiologie), Interféron alpha (pharmacologie), Interféron bêta (pharmacologie), Interféron de type I (pharmacologie), Lignée cellulaire, Protéines de fusion recombinantes (pharmacologie), Protéines recombinantes, Réplication virale (), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- pharmacologie : Antiviraux, Interféron alpha, Interféron bêta, Interféron de type I, Protéines de fusion recombinantes.
- physiologie : Ebolavirus, Virus du SRAS.
- Animaux, Bioterrorisme, Ebolavirus, Lignée cellulaire, Protéines recombinantes, Réplication virale, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Bioterrorism, Cell Line, Chlorocebus aethiops, Ebolavirus (drug effects), Ebolavirus (physiology), Interferon Type I (pharmacology), Interferon-alpha (pharmacology), Interferon-beta (pharmacology), Recombinant Fusion Proteins (pharmacology), Recombinant Proteins, SARS Virus (drug effects), SARS Virus (physiology), Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Interferon Type I, Interferon-alpha, Interferon-beta, Recombinant Fusion Proteins.
- drug effects : Ebolavirus, SARS Virus, Virus Replication.
- physiology : Ebolavirus, SARS Virus.
- Animals, Bioterrorism, Cell Line, Chlorocebus aethiops, Recombinant Proteins.
Abstract
The type 1 interferons (INF-alpha and INF-beta) are potent antiviral agents. Albumin-INF-alpha and albumin-INF-beta are novel recombinant proteins consisting of IFN-alpha or IFN-beta genetically fused to human albumin.
DOI: 10.1159/000140361
PubMed: 18560223
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B21
Links to Exploration step
pubmed:18560223Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.</title>
<author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name>
<affiliation wicri:level="1"><nlm:affiliation>Human Genome Sciences, Inc., Rockville, MD 20850, USA. Mani_Subramanian@hgsi.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Human Genome Sciences, Inc., Rockville, MD 20850</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, Paul A" sort="Moore, Paul A" uniqKey="Moore P" first="Paul A" last="Moore">Paul A. Moore</name>
</author>
<author><name sortKey="Gowen, Brian B" sort="Gowen, Brian B" uniqKey="Gowen B" first="Brian B" last="Gowen">Brian B. Gowen</name>
</author>
<author><name sortKey="Olsen, Aaron L" sort="Olsen, Aaron L" uniqKey="Olsen A" first="Aaron L" last="Olsen">Aaron L. Olsen</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
<author><name sortKey="Paragas, Jason" sort="Paragas, Jason" uniqKey="Paragas J" first="Jason" last="Paragas">Jason Paragas</name>
</author>
<author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name>
</author>
<author><name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W" last="Sidwell">Robert W. Sidwell</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18560223</idno>
<idno type="pmid">18560223</idno>
<idno type="doi">10.1159/000140361</idno>
<idno type="wicri:Area/PubMed/Corpus">001B21</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B21</idno>
<idno type="wicri:Area/PubMed/Curation">001B21</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.</title>
<author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G Mani" last="Subramanian">G Mani Subramanian</name>
<affiliation wicri:level="1"><nlm:affiliation>Human Genome Sciences, Inc., Rockville, MD 20850, USA. Mani_Subramanian@hgsi.com</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Human Genome Sciences, Inc., Rockville, MD 20850</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moore, Paul A" sort="Moore, Paul A" uniqKey="Moore P" first="Paul A" last="Moore">Paul A. Moore</name>
</author>
<author><name sortKey="Gowen, Brian B" sort="Gowen, Brian B" uniqKey="Gowen B" first="Brian B" last="Gowen">Brian B. Gowen</name>
</author>
<author><name sortKey="Olsen, Aaron L" sort="Olsen, Aaron L" uniqKey="Olsen A" first="Aaron L" last="Olsen">Aaron L. Olsen</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
<author><name sortKey="Paragas, Jason" sort="Paragas, Jason" uniqKey="Paragas J" first="Jason" last="Paragas">Jason Paragas</name>
</author>
<author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J" last="Hogan">Robert J. Hogan</name>
</author>
<author><name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W" last="Sidwell">Robert W. Sidwell</name>
</author>
</analytic>
<series><title level="j">Chemotherapy</title>
<idno type="eISSN">1421-9794</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Bioterrorism</term>
<term>Cell Line</term>
<term>Chlorocebus aethiops</term>
<term>Ebolavirus (drug effects)</term>
<term>Ebolavirus (physiology)</term>
<term>Interferon Type I (pharmacology)</term>
<term>Interferon-alpha (pharmacology)</term>
<term>Interferon-beta (pharmacology)</term>
<term>Recombinant Fusion Proteins (pharmacology)</term>
<term>Recombinant Proteins</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Bioterrorisme</term>
<term>Ebolavirus ()</term>
<term>Ebolavirus (physiologie)</term>
<term>Interféron alpha (pharmacologie)</term>
<term>Interféron bêta (pharmacologie)</term>
<term>Interféron de type I (pharmacologie)</term>
<term>Lignée cellulaire</term>
<term>Protéines de fusion recombinantes (pharmacologie)</term>
<term>Protéines recombinantes</term>
<term>Réplication virale ()</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon Type I</term>
<term>Interferon-alpha</term>
<term>Interferon-beta</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Ebolavirus</term>
<term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Interféron bêta</term>
<term>Interféron de type I</term>
<term>Protéines de fusion recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Ebolavirus</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Ebolavirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Bioterrorism</term>
<term>Cell Line</term>
<term>Chlorocebus aethiops</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Bioterrorisme</term>
<term>Ebolavirus</term>
<term>Lignée cellulaire</term>
<term>Protéines recombinantes</term>
<term>Réplication virale</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The type 1 interferons (INF-alpha and INF-beta) are potent antiviral agents. Albumin-INF-alpha and albumin-INF-beta are novel recombinant proteins consisting of IFN-alpha or IFN-beta genetically fused to human albumin.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18560223</PMID>
<DateCompleted><Year>2008</Year>
<Month>08</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1421-9794</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>54</Volume>
<Issue>3</Issue>
<PubDate><Year>2008</Year>
</PubDate>
</JournalIssue>
<Title>Chemotherapy</Title>
<ISOAbbreviation>Chemotherapy</ISOAbbreviation>
</Journal>
<ArticleTitle>Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus.</ArticleTitle>
<Pagination><MedlinePgn>176-80</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1159/000140361</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The type 1 interferons (INF-alpha and INF-beta) are potent antiviral agents. Albumin-INF-alpha and albumin-INF-beta are novel recombinant proteins consisting of IFN-alpha or IFN-beta genetically fused to human albumin.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The in vitro antiviral activity of albumin-IFN-alpha was evaluated against representative bioterrorism viral agents and the severe acute respiratory syndrome virus. Antiviral activity was assessed using inhibition of cytopathic effect and neutral red staining.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">EC(50) values for albumin-IFN-alpha ranged from <0.1 ng/ml for Punta Toro virus to 65 ng/ml for Venezuelan equine encephalitis virus in the neutral red assay. Albumin-IFN-beta showed 75- and 360-fold greater in vitro activity than albumin-IFN-alpha against Ebola virus and severe acute respiratory syndrome, respectively.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Further evaluation of these long-acting albumin-IFN fusion proteins as prophylactic or therapeutic agents against these viral agents of bioterrorism in relevant primate models is warranted.</AbstractText>
<CopyrightInformation>(c) 2008 S. Karger AG, Basel.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Subramanian</LastName>
<ForeName>G Mani</ForeName>
<Initials>GM</Initials>
<AffiliationInfo><Affiliation>Human Genome Sciences, Inc., Rockville, MD 20850, USA. Mani_Subramanian@hgsi.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moore</LastName>
<ForeName>Paul A</ForeName>
<Initials>PA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gowen</LastName>
<ForeName>Brian B</ForeName>
<Initials>BB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Olsen</LastName>
<ForeName>Aaron L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barnard</LastName>
<ForeName>Dale L</ForeName>
<Initials>DL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Paragas</LastName>
<ForeName>Jason</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hogan</LastName>
<ForeName>Robert J</ForeName>
<Initials>RJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sidwell</LastName>
<ForeName>Robert W</ForeName>
<Initials>RW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>N01-AI-85348</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Chemotherapy</MedlineTA>
<NlmUniqueID>0144731</NlmUniqueID>
<ISSNLinking>0009-3157</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C517868">albumin interferon</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>77238-31-4</RegistryNumber>
<NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023482" MajorTopicYN="Y">Bioterrorism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year>
<Month>04</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>03</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>8</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18560223</ArticleId>
<ArticleId IdType="pii">000140361</ArticleId>
<ArticleId IdType="doi">10.1159/000140361</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001B21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:18560223 |texte= Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18560223" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |